Fig. 3.
Mean levels of (A) LH, (B) FSH, (C) E2, (D) SHBG, (E) DHEA-S, and markers of bone turnover—(F) osteocalcin and (G) CTX1—after 12 and 24 wk of treatment with 40 mg estetrol (E4) or placebo in patients with prostate cancer treated with an LHRH agonist (per-protocol population). CTX1 = type I collagen telopeptide; DHEA-S = dehydroepiandrosterone sulfate; E2 = estradiol; E4 = estetrol; FSH = follicle-stimulating hormone; LH = luteinizing hormone; SHBG = sex hormone–binding globulin.